Literature DB >> 32870142

Sleep, sleep spindles, and cognitive functions in drug-naive patients with first-episode psychosis.

Naksidil Torun Yazıhan1, Sinan Yetkin2.   

Abstract

STUDY
OBJECTIVES: Various lines of clinical findings have suggested abnormalities in macro- or microstructural parameters of sleep in patients with schizophrenia. Meanwhile findings are inconclusive due to some confounding factors, such as the heterogeneity of the disorder, drug regimen, and duration of the illness. There are a few studies in the literature that have been conducted on drug-free patients with first-episode psychosis (FEP). Based on this knowledge, we aimed to explore sleep characteristics, sleep spindles, and neuropsychological profiles of the drug-naive patients with FEP.
METHODS: The study sample consisted of 21 drug-naive patients with FEP and 21 healthy participants. Polysomnography recordings were conducted for 2 subsequent nights. A neuropsychological test battery was administered for assessing cognitive functions. The Positive and Negative Syndrome Scale was applied to measure symptom severity of the patients. Spindle detection was performed visually.
RESULTS: According to the results of the study, the patient group's percentage of stage N2 sleep and sleep efficiency index was lower than in the control group. Among sleep spindle parameters, spindle density was found to be reduced in the patient group. The results of neuropsychological tests measuring executive functions, learning, and memory support the idea that there is a global cognitive deterioration from the early course of the disorder. In the psychotic group, negative symptoms were negatively correlated with verbal memory, learning, verbal fluency, and semantic organization. We found that the percentage of stage N3 sleep decreased while negative symptom severity increased. In addition, the percentage of stage N1 sleep increased as negative symptom severity increased. Reduction in stage N3 sleep was associated with an impairment in learning, verbal fluency, and response inhibition. The sleep spindle density and cognitive functions did not show any associations.
CONCLUSIONS: Taken together, these findings suggest that patients with FEP show global cognitive impairment (except for attention and processing speed), which is associated with changes in sleep architecture and higher score in a scale assessing negative symptoms. We conclude that cognitive function and spindle parameters differ nonlinearly among patients with FEP.
© 2020 American Academy of Sleep Medicine.

Entities:  

Keywords:  first-episode psychosis; neuropsychology; schizophrenia; sleep; sleep architecture; sleep spindle

Mesh:

Year:  2020        PMID: 32870142      PMCID: PMC7848935          DOI: 10.5664/jcsm.8776

Source DB:  PubMed          Journal:  J Clin Sleep Med        ISSN: 1550-9389            Impact factor:   4.062


  73 in total

1.  Clinical significance of sleep EEG abnormalities in chronic schizophrenia.

Authors:  Changkook Yang; John W Winkelman
Journal:  Schizophr Res       Date:  2005-12-27       Impact factor: 4.939

2.  Sleep-wake cycles and cognitive functioning in schizophrenia.

Authors:  Vivien Bromundt; Matthias Köster; Angela Georgiev-Kill; Klaus Opwis; Anna Wirz-Justice; Gabriela Stoppe; Christian Cajochen
Journal:  Br J Psychiatry       Date:  2011-01-24       Impact factor: 9.319

Review 3.  Cognition in schizophrenia: impairments, determinants, and functional importance.

Authors:  Christopher R Bowie; Philip D Harvey
Journal:  Psychiatr Clin North Am       Date:  2005-09

Review 4.  The Consortium on the Genetics of Schizophrenia: neurocognitive endophenotypes.

Authors:  Raquel E Gur; Monica E Calkins; Ruben C Gur; William P Horan; Keith H Nuechterlein; Larry J Seidman; William S Stone
Journal:  Schizophr Bull       Date:  2006-11-13       Impact factor: 9.306

Review 5.  Sleep and plasticity in schizophrenia.

Authors:  Kate E Sprecher; Fabio Ferrarelli; Ruth M Benca
Journal:  Curr Top Behav Neurosci       Date:  2015

6.  The course of cognitive functioning over six months in individuals at clinical high risk for psychosis.

Authors:  Mariapaola Barbato; Mark A Colijn; Richard S E Keefe; Diana O Perkins; Scott W Woods; Keith A Hawkins; Bruce K Christensen; Jean Addington
Journal:  Psychiatry Res       Date:  2012-11-16       Impact factor: 3.222

7.  Sleep architecture and its clinical correlates in first episode and neuroleptic-naive patients with schizophrenia.

Authors:  Julie Poulin; Anne-Marie Daoust; Geneviève Forest; Emmanuel Stip; Roger Godbout
Journal:  Schizophr Res       Date:  2003-07-01       Impact factor: 4.939

8.  Anatomical and functional brain abnormalities in drug-naive first-episode schizophrenia.

Authors:  Wenting Ren; Su Lui; Wei Deng; Fei Li; Mingli Li; Xiaoqi Huang; Yuqing Wang; Tao Li; John A Sweeney; Qiyong Gong
Journal:  Am J Psychiatry       Date:  2013-11       Impact factor: 18.112

9.  Neurocognitive deficit in schizophrenia: a quantitative review of the evidence.

Authors:  R W Heinrichs; K K Zakzanis
Journal:  Neuropsychology       Date:  1998-07       Impact factor: 3.295

10.  Sleep Disorders in Early Psychosis: Incidence, Severity, and Association With Clinical Symptoms.

Authors:  Sarah Reeve; Bryony Sheaves; Daniel Freeman
Journal:  Schizophr Bull       Date:  2019-03-07       Impact factor: 9.306

View more
  2 in total

1.  From Memories of Past Experiences to Present Motivation? A Meta-analysis on the Association Between Episodic Memory and Negative Symptoms in People With Psychosis.

Authors:  Matthias Pillny; Katarina Krkovic; Laura Buck; Tania M Lincoln
Journal:  Schizophr Bull       Date:  2022-03-01       Impact factor: 7.348

2.  Association of polygenic risk for schizophrenia with fast sleep spindle density depends on pro-cognitive variants.

Authors:  Claudia Schilling; Lea Zillich; Michael Schredl; Josef Frank; Emanuel Schwarz; Michael Deuschle; Andreas Meyer-Lindenberg; Marcella Rietschel; Stephanie H Witt; Fabian Streit
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2022-06-20       Impact factor: 5.760

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.